[1] Jemal A, Bray F, Center M M, et al. Global cancer statistics[J]. CA Cancer J Clin, 2011, 61(2): 69-90.
[2] Wagstaff A J, Keam S J, McCormack P L. Bevacizumab plus platinum based chemotherapy: in advanced nonsmall cell lung cancer[J]. Bio Drugs. 2009, 23(3): 187-196.
[3] Ranieri G, Gasparini G. Angiogenesis and angiogenesis inhibitors: a new potential anticancer therapeutic strategy[J]. Current Drug Targets Immune, Endocrine and Metabolic Disorders, 2001, 1(3): 241-253.
[4] Zhang Z, Huang Y, Newman K, et al. Reexpression of human somatostatin receptor gene 2 gene mediated by oncolytic adenovirus increases antitumor activity of tumor necrosis factorrelated apoptosis inducing ligand against pancreatic cancer[J]. Clinical Cancer Research: an official journal of the American Association for Cancer Research, 2009, 15(16): 5154-5160.
[5] Zhang Y, Gu J, Zhao L, et al. Complete elimination of colorectal tumor xenograft by combined manganese superoxide dismutase with tumor necrosis factor related apoptosis inducing ligand gene virotherapy[J]. Cancer Research, 2006, 66(8): 4291-4298.
[6] Wang S B, Tan Y, Lei W, et al. Complete eradication of xenograft hepatoma by oncolytic adenovirus ZD55 harboring TRAIL IETD Smac gene with broad antitumor effect[J]. Human Gene Therapy, 2012, 23(9): 992-1002.
[7] Zhang Y, Qin X, Zhang Y, et al. Combination of ZD55 MnSOD therapy with 5 FU enhances antitumor efficacy in colorectal cancer[J]. Journal of Cancer Research and Clinical Oncology, 2008, 134(2): 219-26.
[8] Ma G, Kawamura K, Li Q, et al. Combinatory cytotoxic effects produced by E1B 55kDa deleted adenoviruses and chemotherapeutic agents are dependent on the agents in esophageal carcinoma[J]. Cancer Gene Therapy, 2010, 17(11): 803-813.
[9] Kadota K, Huang C L, Liu D, et al. Combined therapy with a thymidylate synthase inhibiting vector and S 1 has effective antitumor activity against 5 FU resistant tumors[J]. International Journal of Oncology. 2011, 38(2): 355-63.
[10] Keane M M, Ettenberg S A, Nau M M, et al. Chemotherapy augments TRAIL induced apoptosis in breast cell lines[J]. Cancer research, 1999, 59(3): 734-741.
[11] Ashkenazi A, Pai R C, Fong S, et al. Safety and antitumor activity of recombinant soluble Apo2 ligand[J]. The Journal of Clinical Investigation, 1999, 104(2): 155-162.
[12] Mizutani Y, Nakanishi H, Yoshida O, et al. Potentiation of the sensitivity of renal cell carcinoma cells to TRAIL mediated apoptosis by subtoxic concentrations of 5 fluorouracil[J]. European Journal of Cancer, 2002, 38(1): 167-176.